Qatar's HMC Launches In-House Whole Exome Sequencing, Expands Precision Medicine with 20 Million Annual Diagnostic Tests
Key Insights
Hamad Medical Corporation laboratories perform over 20 million diagnostic tests annually, including approximately 153,000 genetic tests for inherited disorders, blood cancers (search), and newborn screening.
HMC has launched in-house Clinical Whole Exome Sequencing for the first time, alongside new pharmacogenomics and thrombophilia testing services to advance personalized medicine.
The Cell Therapy Laboratory reported a 19% increase in stem cell-based bone marrow transplants for adult cancer patients compared to the previous year.
Qatar's Hamad Medical Corporation (HMC) has achieved a significant milestone in laboratory diagnostics, performing more than 20 million diagnostic tests annually, including approximately 153,000 genetic tests, as the institution advances its digital transformation and precision medicine capabilities. The developments, disclosed by Dr. Einas Al Kuwari, Chairman of Laboratory Medicine and Pathology at HMC, mark what she described as "a strategic shift toward building a smart national laboratory system based on innovation, technology, scientific research, and skilled professionals."
The scale of operations underscores HMC's central role in Qatar's healthcare ecosystem, with the Genetic Diagnostics Laboratory conducting testing for inherited disorders, genetic mutations linked to blood cancers (search) and lymph node diseases, as well as premarital and newborn screenings.
In-House Whole Exome Sequencing Launched
In a major step for precision medicine, HMC has launched in-house Clinical Whole Exome Sequencing (WES) for the first time. The new capability, introduced alongside pharmacogenomics and thrombophilia testing services, expands the institution's ability to deliver personalized diagnosis and treatment. Dr. Al Kuwari highlighted these additions as central to developing HMC's precision medicine services.
The digital transformation underpinning these advances aligns with Qatar National Vision 2030, which aims to build an integrated digital healthcare system driven by innovation, data, and advanced technologies. HMC has adopted advanced digital systems to manage laboratory operations and integrate analytical instruments with medical records electronically, delivering test results securely and immediately while reducing turnaround times and improving accuracy and quality.
Cell Therapy and Transplantation Advances
The Cell Therapy Laboratory continues to provide stem cell-based bone marrow transplants for adult cancer patients, recording a 19% increase compared to the previous year. Qatar's only histocompatibility laboratory supports kidney and bone marrow transplant programs using advanced technologies that reduce the risk of immune rejection and improve transplant outcomes. The laboratory also offers advanced tests, including cell-free DNA (cfDNA) and immune cell function testing, to improve post-transplant monitoring.
Blood Transfusion Self-Sufficiency Achieved
Qatar has achieved self-sufficiency in blood and blood components through strong donor participation. HMC has secured international accreditation for 11 sites and introduced the use of Low Titer O Whole Blood for critically injured trauma patients, improving survival rates through faster treatment of severe bleeding. Additionally, HMC has introduced cryopreservation technology for rare blood group red blood cell units, allowing them to be stored for up to 30 years, strengthening preparedness for complex and rare clinical cases.
Clinical Biochemistry and Anatomical Pathology
In clinical biochemistry, HMC has introduced therapeutic drug monitoring, lipoprotein(a) testing to support early cardiovascular disease (search) detection, expanded zinc and preeclampsia (search) screening, and deployed advanced polymerase chain reaction (PCR) systems for respiratory virus testing.
The anatomical pathology laboratory receives more than 60,000 tissue samples annually, with cancer or suspected cancer cases accounting for approximately 13% of total cases. The growing volume reflects increasing demand for histopathology services and their central role in early cancer detection, supported by advanced diagnostic technologies that improve accuracy and speed clinical decision-making.
Antimicrobial Resistance and Medical Education
The microbiology department continues to strengthen efforts to combat antimicrobial resistance by developing national surveillance profiles, implementing the One Health approach, and expanding diagnostic supervision and infection prevention programs that improve diagnostic efficiency, reduce costs, and enhance patient safety.
On the medical education front, the department organized Qatar's first pathology conference and was accredited as a venue for the Royal College of Pathologists Fellowship (FRCPath) examinations, postgraduate and fellowship training programs, and strengthened academic collaboration with Qatar University.
Dr. Al Kuwari concluded that the achievements represent a comprehensive advancement in laboratory medicine and pathology, further enhancing healthcare quality and patient safety in Qatar.